Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
India5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
250 fő vett részt
Kezdés
2023. dec. 14.
Befejezés
2024. febr. 26.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Fluarix Tetra Vaccine
A regiszteradat frissítve
2025. március 28.

Ki vehet részt

Életkor
65 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female participants aged >= 65 years of age
  • Participants and/or legally acceptable representative (s) (LAR) who in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits
  • Written or witnessed/thumb printed informed consent obtained from the participant and/or participant's LAR(s) after the study has been explained according to the local authority requirements and prior to performance of any study-specific procedure

Ki nem vehet részt

  • History of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • Receipt of licensed vaccine, immune sera and/or any blood products, or an investigational trial agent within previous 30 days or planned during their participation in the trial
  • Receipt of any flu vaccine within 6 months before trial start or any other vaccine within 30 days before the trial
  • Altered immune status or chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents within six months prior to administration of trial vaccine
  • History of acute infectious disease or acute respiratory illness needing antibiotics or antivirals in the previous 7 days, based on investigator's judgement
  • Receipt of any dose of a Coronavirus Disease 2019 (COVID-19) vaccine within 15 days of trial start
  • History of Guillain-Barré Syndrome
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the trial
  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or laboratory screening tests
  • If a participant candidate has fever, the trial vaccination should be postponed to when the fever has resolved for at least 2 days (temporary exclusion criterion). Fever is defined as temperature >=38.0 degree Celsius (°C) (100.4 degrees Fahrenheit [°F]) by any route. The preferred location for measuring temperature will be oral route

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.

A vizsgálat csoportja

  • Quadrivalent seasonal influenza (FLU D-QIV) vaccine groupA vizsgált kezelés

    Participants received 1 dose of seasonal FLU vaccine at Day 1.

    Kezelés: Fluarix Tetra Vaccine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Single-arm, Open-label, Multi-center, Phase IV Trial to Evaluate the Reactogenicity, Safety, and Immunogenicity of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
Publikációk
A regiszteradat frissítve
2025. március 28.